By Gilang Cahya 
Working with human stem cells that form a kind of "mini intestine-in-a-dish," Johns Hopkins Medicine scientists say they have found several molecular mechanisms for COVID-19-related diarrhea, suggesting potential ways to control it. These groundbreaking findings, detailed in the July 30 issue of Cellular and Molecular Gastroenterology and Hepatology, shed new light on a persistent and often debilitating symptom of SARS-CoV-2 infection, offering a crucial step towards developing effective therapeutic interventions.
The research utilized human intestinal organoids, or enteroids, a sophisticated laboratory model that replicates the structure and function of the human intestinal lining. By exposing these enteroids to live SARS-CoV-2 virus, researchers were able to observe and analyze the virus’s impact on intestinal cells at a molecular level. This innovative approach allowed scientists to bypass the complexities of studying the human gut in vivo and gain a precise understanding of the biochemical processes underlying COVID-19-induced gastrointestinal distress.
The Pervasive Problem of COVID-19 Diarrhea
While the respiratory symptoms of COVID-19 have dominated public discourse, gastrointestinal manifestations, particularly diarrhea, have been a significant and often overlooked aspect of the illness. Estimates suggest that as many as half of all individuals infected with SARS-CoV-2 experience diarrhea. This symptom, while not typically life-threatening in the same vein as diseases like cholera, can serve as a critical indicator of disease severity and a predictor of the development of long COVID.
"While COVID-19 diarrhea is not life-threatening like cholera, it can often predict a severe case and also who gets the long covid syndrome," stated Dr. Mark Donowitz, Emeritus Professor of Medicine and Physiology at the Johns Hopkins University School of Medicine, and a lead author of the study. Long COVID, a complex and multifaceted condition affecting a substantial portion of survivors, is characterized by a wide array of persistent and debilitating symptoms, including chronic pain, cognitive dysfunction (brain fog), shortness of breath, chest pain, and profound fatigue. The link between initial gastrointestinal symptoms and the development of long COVID underscores the importance of understanding the gut’s role in the disease’s pathogenesis.
Unraveling the Molecular Pathways
Previous understanding of COVID-19’s impact on the gut was limited. It was known that the virus utilizes the ACE2 enzyme, which is abundant in the intestinal lining, as a point of entry into cells. The TMPRSS2 enzyme also plays a crucial role in facilitating viral entry. However, the precise molecular mechanisms by which the virus triggers diarrhea remained largely elusive. This new research by the Johns Hopkins team significantly advances our comprehension by painting a more complete picture of these mechanisms.
The enteroid model, cultivated from human stem cells, provides a unique three-dimensional structure that mimics the single-layered epithelium of the normal intestine, oriented in the same directional manner. This allows for an accurate representation of cellular interactions and responses. When exposed to SARS-CoV-2, these enteroids exhibited notable alterations in protein expression and cellular function, providing direct evidence of the virus’s disruptive effects on intestinal physiology.
Beyond Traditional Diarrhea Mechanisms
In typical diarrheal diseases, disruptions in transport proteins responsible for moving molecules across cell membranes are a common culprit. These disruptions often lead to impaired absorption of sodium and chloride, coupled with increased secretion of chloride, resulting in fluid imbalance and diarrhea. The Johns Hopkins study revealed that COVID-19 diarrhea involves both of these processes, a characteristic shared with many other diarrheal conditions.
However, a key distinction emerged in the study. While many diarrheal diseases involve the activation of the protein responsible for cystic fibrosis, the research identified a different class of proteins, specifically calcium-activated chloride channels, as being central to chloride secretion in COVID-19 diarrhea. This finding suggests a unique molecular signature for SARS-CoV-2-induced gastrointestinal upset.
Furthermore, the study uncovered an unusual combination of factors contributing to COVID-19 diarrhea. Unlike many diarrheal diseases, which are typically caused by either direct damage to transport proteins or by the accompanying inflammation, the researchers observed evidence of both mechanisms at play in the enteroid cells. This dual assault on intestinal function highlights the multifaceted nature of the virus’s impact.
The Role of Inflammation and Potential Therapeutic Avenues
The researchers posit that the inflammation observed in the context of COVID-19 diarrhea may mirror the inflammatory responses triggered by the virus in other organs, such as the lungs. This analogy opens up promising avenues for therapeutic intervention. By understanding that inflammation plays a significant role, scientists can now explore the potential of inhibitors that target these inflammatory pathways as a means to combat COVID-19 diarrhea. This could involve repurposing existing anti-inflammatory drugs or developing novel targeted therapies.
The implications of this research extend beyond immediate symptom relief. The persistent presence of the virus in the intestine for extended periods is a critical factor in the development of long COVID. Dr. Donowitz remarked, "The precise mechanisms of long COVID are a big mystery, although we now know that the virus can persist in the intestine for a long time. The next big question is to determine what exactly allows the virus to live in the intestine and what allows the virus to live over a long period of time." This ongoing research aims to bridge this knowledge gap, potentially identifying strategies to clear the virus from the gut and mitigate the long-term consequences of infection.
Broader Impact and Future Directions
The findings from Johns Hopkins Medicine represent a significant leap forward in our understanding of COVID-19’s complex pathology. By elucidating the specific molecular mechanisms behind COVID-19-related diarrhea, this research provides a foundation for the development of targeted therapies. This could lead to improved patient outcomes, particularly for those at risk of developing long COVID.
The study’s reliance on enteroids, a cutting-edge model system, underscores the growing importance of organoid technology in biomedical research. These "mini organs" offer an unprecedented ability to study human physiology and disease in a controlled laboratory setting, accelerating the pace of discovery.
The research was supported by grants from the Johns Hopkins University School of Medicine Dean Durso Award and the National Institutes of Health, including the National Institute of Diabetes and Digestive and Kidney Diseases (RO1 DK26523, RO1 DK116352; P30DK089502). This collaborative effort involved a multidisciplinary team of researchers from Johns Hopkins Medicine, the Johns Hopkins Bloomberg School of Public Health, and the University of New Mexico Health Sciences Center and Center for Global Health.
Moving forward, the research team plans to further investigate the specific inflammatory pathways involved and to explore the efficacy of potential inhibitor drugs in preclinical models. The ultimate goal is to translate these laboratory findings into clinical applications that can alleviate the suffering of millions affected by COVID-19 and its lingering sequelae. The quest to fully understand and combat the long-term effects of this global pandemic continues, with this latest discovery offering a beacon of hope for improved patient care and recovery.
